TRELEGY is for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and for reducing exacerbations in patients with a history of exacerbations. TRELEGY is NOT indicated for relief of acute bronchospasm or asthma.
contact gsk
1-877-512-1344
TRELEGY—the only once-daily triple therapy (ICS/LABA
/LAMA
) for COPD delivered in a single inhaler
one
inhaler.
once
daily.
one
co-pay.*
*One co-pay is not a guarantee of coverage or lower out-of-pocket costs for patients than alternative treatments. Formulary status and patient out-of-pocket costs may vary, may be up to the prescription’s retail cost, and are subject to change.
one
inhaler.
once
daily.
one
co-pay.*
*One co-pay is not a guarantee of coverage or lower out-of-pocket costs for patients than alternative treatments. Formulary status and patient out-of-pocket costs may vary, may be up to the prescription’s retail cost, and are subject to change.
Simplify the delivery of an
ICS, LABA, and LAMA with once-daily TRELEGY
For patients with COPD, once-daily dosing with TRELEGY may help to simplify triple therapy. TRELEGY does not replace a rescue inhaler. Patients should be provided a short-acting beta2-agonist, such as albuterol, to treat acute symptoms and instructed on how it should be used.
An ICS to reduce inflammation
A LABA to increase bronchodilation
A LAMA to reduce bronchoconstriction
Keeping samples on hand may help get patients started on once-daily TRELEGY
REQUEST SAMPLESExplore more clinical data
on exacerbations, lung function, and health-related quality of life
VIEW CLINICAL TRIALSFor appropriate patients with COPD
on maintenance medication who need improvement in lung function or reduction in exacerbations, TRELEGY offers an ICS, LABA, and LAMA in a single inhaler
VIEW PATIENT PROFILEDiscover TRELEGY ELLIPTA –
an innovation in COPD treatment
Stay up-to-date with new information